Avirmax Biopharma Inc., based in the San Francisco Bay Area, is a clinical stage biopharmaceutical company focused on the innovation and development of targeted gene based therapies to treat chronic and age-related degenerative ocular diseases. We bring integrated solutions in engineering and optimization of adeno-associated virus (AAV) vectors, extensive biopharmaceutical development experience, and expertise in robust product supply.